Antibodies Against p53 and Breast Cancer Risk
Author Information
Author(s): Lenner P, Wiklund F, Emdin S O, Arnerlöv C, Eklund C, Hallmans G, Zentgraf H, Dillner J
Primary Institution: Umeå University
Hypothesis
Do p53 autoantibodies in serum predict breast cancer risk and prognosis?
Conclusion
The presence of anti-p53 antibodies is significant for both the risk of developing breast cancer and the risk of dying from it.
Supporting Evidence
- Presence of high-level reactivity of p53 antibodies was more common among breast cancer cases than controls.
- There was a significant negative correlation between presence of p53 antibodies and survival.
- T-stage, age, and presence of anti-p53 antibodies were significant independent prognostic variables.
Takeaway
This study found that people with certain antibodies in their blood are more likely to have breast cancer and may not live as long if they do.
Methodology
The study measured p53 antibodies in serum samples from 165 breast cancer patients and 330 healthy controls using ELISA and confirmed with Western blotting.
Participant Demographics
Median age of patients was 51 years, with a range of 25 to 64 years.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI 2.40–50.43 for ELISA; 95% CI 3.0–59.4 for Western blot
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website